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A strong association between ERAP1 and ankylosing spondylitis (AS) was recently identiﬁed by the
Wellcome Trust Case Control Consortium and the Australo-Anglo-American Spondylitis Consortium
(WTCCC-TASC) study. ERAP1 is highly polymorphic with strong linkage disequilibrium evident across the
gene. We therefore conducted a series of experiments to try to identify the primary genetic association(s)
with ERAP1. We replicated the original associations in an independent set of 730 patients and 1021 controls,
resequenced ERAP1 to deﬁne the full extent of coding polymorphisms and tested all variants in additional
association studies. The genetic association with ERAP1 was independently conﬁrmed; the strongest associ-
ation was with rs30187 in the replication set (P 5 3.4 3 10
23). When the data were combined with the original
WTCCC-TASC study the strongest association was with rs27044 (P 5 1.1 3 10
29). We identiﬁed 33 sequence
polymorphisms in ERAP1, including three novel and eight known non-synonymous polymorphisms. We
report several new associations between AS and polymorphisms distributed across ERAP1 from the
extended case–control study, the most signiﬁcant of which was with rs27434 (P 5 4.7 3 10
27). Regression
analysis failed to identify a primary association clearly; we therefore used data from HapMap to impute gen-
otypes for an additional 205 non-coding SNPs located within and adjacent to ERAP1. A number of highly sig-
niﬁcant associations (P < 5 3 10
29) were identiﬁed in regulatory sequences which are good candidates for
causing susceptibility to AS, possibly by regulating ERAP1 expression.
INTRODUCTION
Ankylosing spondylitis (AS) is a highly heritable form of
spondyloarthropathy with an oligogenic component to suscep-
tibility. The best known contribution to AS comes from the
HLA-B27 immune response gene, accounting for 37% of
the total genetic risk (1). HLA-B27 is virtually a prerequisite
for the development of AS but on its own it is insufﬁcient
to cause the disease (1). In 2007, the Wellcome Trust
Case Control Consortium and the Australo-Anglo-American
Spondylitis Consortium (WTCCC-TASC) performed a gene-
targeted association study of 14 500 nsSNPs in 1000 AS
cases and 1500 controls. They conﬁrmed the known strong
association with the major histocompatibilty complex
(MHC) and also provided preliminary evidence for several
non-MHC associations. Five nsSNPs in ERAP1 were geno-
typed, all producing signiﬁcant associations with AS with a
peak P-value of 1   10
26 (2). The association with endo-
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known as ARTS1, was subsequently replicated in an
independent North American cohort and recently further con-
ﬁrmation has come from case–control and familial association
studies (2–4).
ERAP1 encodes a multi-functional zinc-metallopeptidase
belonging to the M1 family of aminopeptidases with several
proposed biological functions that make it a strong candidate
in AS. ERAP1 has been shown to bind directly to the extracellu-
lar domain of TNFR1 in vitro and promote its IL-1b-mediated
ectodomain cleavage to generate 27–34 kDa soluble TNFR1
(5). Cleavage may require ERAP1 to be in a calcium-dependent
complex with nucleobindin 2 (NUCB2) and RNA-binding motif
protein, X-linked (RBMX) (6–9). This ERAP1–NUCB2–
RBMX complex is also required for the constitutive release of
full length 55 kDa TNFR1 within exosome-like vesicles to the
extracellular compartment (6,7). Such ERAP1 assisted gener-
ation of extracellular TNFR1 could be crucial for regulating
the bioactivity of TNF which plays a central role in regulation
of inﬂammation. A direct correlation has also been demon-
strated between increased membrane-associated ERAP1
protein and increased soluble IL-6Ra and IL-1RII, consistent
with their ectodomain cleavage (9,10).
In the endoplasmic reticulum (ER), ERAP1 has the potential
to trim peptide antigens to optimal length for binding to MHC
class I molecules (11). Complex proteins are initially degraded
in the cytosol by the multi-unit proteasome complex, typically
generating peptide fragments up to 25 amino acids in length
(12). Such peptide antigens and their N-terminal extended pre-
cursors are subsequently transported into the ER by the trans-
porter associated with antigen processing that preferentially
transports peptides 8–16 residues in length (13–16). Nascent
MHC class I molecules typically bind short peptide fragments
8–9 residues long and transport them to the cell surface for
presentation to T cells. ERAP1 is expressed in the lumen of
the ER where peptide loading to MHC class I molecules
takes place. Here it preferentially trims substrates 10–16 resi-
dues long whilst sparing peptides 8–9 residues in length, the
optimal length for binding MHC class I molecules (17,18).
Determining the precise role of ERAP1 in susceptibility to
AS is now a major research goal. There have now been
several studies indicating association between AS and
ERAP1 but no ﬁne-mapping studies have previously been
reported. Here we report the ﬁrst UK replication in a large
independent cohort of cases and controls. Subsequently, we
have systematically identiﬁed all common ERAP1 coding var-
iants present in AS patients and genotyped them in a large
extended case–control study. We report a number of new
associations and have attempted to correlate the strongest
associations with potentially important functions of the
ERAP1 protein and its expression.
RESULTS
Independent ERAP1 replication study
We genotyped four SNPs from the initial WTCCC-TASC
study in an independent cohort of 730 AS cases and 1021 con-
trols. All ERAP1 SNPs were signiﬁcantly associated with AS
(Table 1). This data was then combined with that from the
WTCCC-TASC study (1000 AS cases and 4379 controls)
and a meta-analysis performed. All SNPs achieved a greater
level of signiﬁcance with the most signiﬁcant association
seen with rs30187 in the replication study (P ¼ 3.4   10
23)
and with rs27044 in the combined data set (P ¼ 1.1   10
–9).
ERAP1 sequencing
In the 48 individuals with AS who were sequenced we
observed 33 sequence variants shown in Table 2, 28 of
which had been previously reported; 14 were known coding
SNPs, three were SNPs located close to exon–intron bound-
aries (within 25 nucleotides of an exon) and two SNPs were
identiﬁed in the 50-UTR predicted to encode the ERAP1 pro-
moter (19). The remaining nine known sequence variants
were intronic (within 40–100 nucleotides of an exon) or
downstream of the STOP codon in exon 20. We also found
ﬁve new sequence variants in ERAP1, three of which are non-
synonymous variants in highly conserved amino acids present
in single individuals. The ﬁnal two novel variants observed
were intronic (variants 2 and 5). Five rare coding HapMap
SNPs [minor allele frequencies (MAF) , 0.04] were not
observed in this study.
Extended ERAP1 case control study
We genotyped 23 ERAP1 polymorphisms [excluding the
sequence variants exhibiting strong linkage disequilibrium
(LD)] in 1604 AS cases and 1021 healthy controls. As
expected (due to the overlap of AS cases and controls with
previous studies), we observed a strong association between
AS and the ﬁve SNPs (rs30187, rs27044, rs2887987,
rs17482078 and rs10050860) reported in the initial
WTCCC-TASC study (Table 3). We also observed highly sig-
niﬁcant (P , 9   10
25) associations with four additional
ERAP1 SNPs (rs26653, rs27434, rs1065407 and rs13167972),
the most strongly associated being rs27434 (4.7   10
27) and
rs1065407 (7.5   10
27). We also report weak associations
with two other SNPs rs28366066 (P ¼ 0.009) and rs469876
(P ¼ 5.9   10
24), all of which were not part of the original
WTCCC-TASC study. Two of the new variants identiﬁed by
sequencing (see novel variants 3 and 4 in Tables 2 and 3)
were only observed in patients with AS: four AS patients
were heterozygous for novel variant 3, resulting in a valine/
isoleucine substitution; two other AS patients were hetero-
zygous for novel variant 4, resulting in a substitution of
arginine for cysteine.
Conditional logistic regression was performed on the six
SNPs in ERAP1 (rs27434, rs1065407, rs30187, rs26653,
rs27044 and rs17482078) that were most strongly associated
with AS in the extended study. This was to test whether any
individual SNP was independently associated with AS after
controlling for associations arising from the other ﬁve SNPs
on the haplotype. When all the other ﬁve markers were con-
trolled for individually in this way, no single marker showed
obvious residual association (P . 0.1) (Table 4A). We also
tested whether controlling for the association arising from
each SNP individually left any residual association with the
remaining haplotype. In this case, for each marker tested indi-
vidually, there was strong residual haplotypic association
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each of these SNPs are associated with AS they cannot dis-
tinguish any particular individual SNP as being primarily
responsible for the association at the locus, probably because
of the tight LD across the locus. The data are consistent
either with there being a single predominant associated
variant or with existence of multiple associated alleles. Our
data have insufﬁcient power to distinguish between these
two possibilities.
Therefore, we imputed genotypes for an additional 205
SNPs within and surrounding ERAP1 using our genotype
data and data from HapMap (Supplementary Material, 1) to
assess the level of association across this region. We observed
many additional SNPs strongly associated with AS from the
imputation, including 16 SNPs which obtained a higher level
of signiﬁcance than any SNP from our case–control study
(Fig. 1). The most signiﬁcant associations were with a rare
intron 19 SNP, rs27689 (96 132 957 bp, MAF ¼ 0.07, imputa-
tion quality score 0.88, P ¼ 3.1   10
29) and a group of intro-
nic SNPs in very strong LD, the most signiﬁcant of which was
the intron 16 SNP rs27043 (96 143 055 bp, imputation quality
score 0.99, P ¼ 3.2   10
29).
Comparison with ERAP1 cis-SNP expression
P-values for imputed/genotyped SNPs associations with AS in
our study were compared with P-values for association with
ERAP1 expression from the previous study (20). Only a
subset of 32 SNPs were used in both studies but these data
showed a correlation (using probe 209788_s_at) between the
strength of SNP association with AS and strength ofassociation
with ERAP1 expression (r ¼ 0.75, P , 0.0001) (Fig. 2). The
SNPs showing greatest association with ERAP1 expression
from the previous study were rs28096 (1.6   10
232) and
rs27434 (2.7   10
232) which are also strongly associated with
AS in our extended case–control/imputation study (7.8  
10
28 and 4.7   10
27, respectively).
Molecular modeling of ERAP1 protein structure
MolecularmodelingofERAP1suggestsathree-domainprotein
structure surrounding a central Zn atom. Only rs2287987
(Met349Val) was located close to the HEXXH-(X18)-E
zinc-binding motif whereas the remaining variants were
dispersed widely across the predicted structure (Fig. 3).
DISCUSSION
We have robustly conﬁrmed the genetic association between
AS and ERAP1, ﬁrst in an independent replication study in
UK subjects and subsequently with additional markers in a
further case–control study. In addition to 14 known coding
polymorphisms, we identiﬁed three novel coding variants in
ERAP1, two of which were observed only in AS patients.
Finally, we found six new associations with SNPs in ERAP1
with AS, and many additional markers by imputation which
are possible candidates for the causative variant(s) in this gene.
The strongest associations identiﬁed were with rs27434
(4.7   10
27) in the extended case–control study and with
rs27689 (3.1   10
29) and rs27043 (3.2   10
29) by imputa-
Table 1. Cochrane–Armitage test of trend for replication cohort and meta-analysis for combined cohort (WTCCC-TASC UK AS cases plus replication AS cases
compared with 1958 British Birth Cohort, non-AS WTCCC disease groups and replication controls)
SNP Minor allele Replication cohort Combined cohort
Case MAF
(n ¼ 730)
Control MAF
(n ¼ 1021)
OR P-value Case MAF
(n ¼ 1730)
Control MAF
(n ¼ 5400)
OR P-value
rs27044 G 0.31 0.27 1.2 3.9   10
23 0.33 0.27 1.3 1.1   10
29
rs10050860 T 0.19 0.23 0.8 6.7   10
23 0.18 0.23 0.8 9   10
28
rs30187 T 0.39 0.34 1.2 3.4   10
23 0.40 0.34 1.3 5   10
29
rs2287987 C 0.18 0.23 0.8 3.6   10
23 0.18 0.23 0.8 5.4   10
28
Table 2. ERAP1 sequence variants identiﬁed by sequencing, including their
location and amino acid change in 48 AS cases
SNP Minor
allele
Position Location/
exon
Amino acid
change
rs28366066 A 96169981 50-UTR Intronic
rs151949 G 96169601 50-UTR Intronic
rs26653 C 96165006 2 Pro127Arg
rs27528 T 96162281 IVS3þ40 Intronic
rs26618 C 96156592 5 Ile276Met
Novel variant 1 T 96156570 5 Asp284Asn
rs27895 T 96155299 6 Gly346Asp
rs2287987 C 96155291 6 Met349Val
rs27434 A 96155268 6 Ala356
rs27640 T 96153661 IVS8210 Intronic
rs3213809 A 96153589 8 His417
rs27529 A 96152064 9 Ser453
rs11743410 G 96151015 IVS11265 Intronic
rs30186 G 96150203 IVS11259 Intronic
rs30187 T 96150086 11 Lys528Arg
rs30379 T 96148016 IVS1226 Intronic
rs10050860 T 96147966 12 Asp575Asn
Novel variant 2 C 96147891 IVS12þ39 Intronic
rs469758 C 96147471 IVS13240 Intronic
rs469783 C 96147280 13 Ala637
Novel variant 3 T 96147252 13 Val647Ile
rs469876 G 96147162 IVS13þ85 Intronic
rs17482078 T 96144622 15 Arg725Gln
rs27044 G 96144608 15 Gln730Glu
Novel variant 4 G 96144590 15 Cys736Arg
ENSSNP12878388 T 96143311 16 Leu763
Novel variant 5 C 96143114 IVS16þ40 Intronic
rs17481856 A 96142564 17 Leu848
rs1065407 G 96137839 IVS19þ25 Intronic
rs3822682 G 96123970 20 Non-coding
rs27582 A 96123651 20 Non-coding
rs27980 G 96122584 20 Non-coding
rs13167972 G 96142564 20 Non-coding
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ERAP1, associations were observed throughout the 145 kb
investigated. Consequently locating the primary association
will be extremely difﬁcult using a solely genetic approach in
white European cohorts alone (Fig. 1). Conditional logistic
regression analysis performed on the six most signiﬁcant
genotyped markers from the extended case–control study
(which focused on coding SNPs and potential splice-site
variants) did not allow us to identify an obvious primary
association. However, a contribution to a functional effect
by any of these SNPs on ERAP1 cannot be completely
excluded from this analysis alone. The polymorphism
rs27434 contributes to the conserved HEXXH-(X18)-E zinc-
binding motif of ERAP1 and the modeled protein structure
of ERAP1 suggests rs2287987 is also in close proximity to
the catalytic domain (Fig. 3). However, rs27434 seems extre-
mely unlikely to have any effect on its activity because it is a
synonymous polymorphism. Goto and colleagues reported that
rs30187 caused a signiﬁcant reduction in aminopeptidase
activity towards a synthetic peptide substrate, resulting in
2–3-fold decrease in substrate afﬁnity. Using these data and
molecular modeling of the putative ERAP1 substrate pocket
they hypothesized that this residue contributes to substrate-
binding afﬁnity with the enzyme (21). Finally, rs1065407 is
located 17 nucleotides 30 of the exon 19 splice site that
results in a premature stop codon in isoform 1 of ERAP1.
A number of the most strongly associated SNPs from the
imputed data also reside within introns 18 and 19. The impor-
tance of abnormalities of splicing in causing disease has been
highlighted recently (22,23).
Recent studies suggest that ERAP1 expression traits may be
under cis-regulatory control of expression (20,24,25). Such
heritable allelic expression is common throughout the human
genome (26). We identiﬁed a correlation between the strength
of ERAP1 SNPs association with AS and strength of the same
SNPs association with ERAP1 transcript abundance from a
previous expression study (20) This suggests cis-SNP control
of ERAP1 expression may be of importance in AS, but
expression studies that relate these SNPs to individual
Table 3. Case and control MAF, odds ratios (OR), upper and lower 95% conﬁdence limits (95% CI), P-values and the power to detect an association to an OR of
1.2 are shown for the SNPs genotyped in the ERAP1 case–control study
SNP Case MAF (n ¼ 1604) Control MAF (n ¼ 1021) OR 95% CI P-value Power to detect
rs28366066 0.06 0.08 0.74 1.07–1.70 0.009 41%
rs151949 0.37 0.39 0.92 0.96–1.22 0.17 89%
rs26653 0.33 0.27 1.3 0.68–0.87 8.4   10
25 86%
rs27582 0.26 0.25 1.02 0.79–1.28 0.59 82%
rs26618 0.23 0.24 0.99 0.79–1.27 0.97 81%
NV1 0.00 0.00 N/A N/A N/A N/A
rs27895 0.06 0.07 1.07 0.85–1.34 0.48 36%
rs2287987 0.18 0.23 0.76 1.15–1.52 1.4   10
24 83%
rs27434 0.26 0.20 1.44 0.6–0.8 4.7   10
27 82%
rs3213809 0.15 0.15 0.96 0.8–1.15 0.76 67%
rs30187 0.40 0.34 1.32 0.67–0.85 4.9   10
26 89%
rs10050860 0.18 0.23 0.75 1.16–1.54 1.2   10
24 83%
NV2 0.005 0.004 1.23 0.17–3.8 0.6 7%
rs469783 0.47 0.42 1.22 1.08–1.37 5.9   10
24 90%
NV3 0.001 0 N/A N/A 0.1 N/A
rs469876 0.25 0.25 1.01 0.89–1.16 0.72 82%
rs27044 0.34 0.27 1.36 0.65–0.83 1.6   10
26 86%
rs17482078 0.18 0.23 0.73 1.19–1.59 4   10
25 83%
NV4 0.003 0 N/A N/A 0.25 N/A
ENSSNP12878388 0.06 0.08 0.79 1.01–1.6 0.05 41%
NV5 0.01 0.01 1.19 0.24–1.76 0.6 10%
rs17481856 0.14 0.14 0.98 0.84–1.24 0.81 65%
rs1065407 0.29 0.36 0.74 1.20–1.53 7.5   10
27 87%
rs27980 0.32 0.32 1.02 0.9–1.17 0.7 87%
rs13167972 0.33 0.39 0.74 1.17–1.51 9.1   10
26 89%
Table 4. Conditional logistic regression analysis of most associated ERAP1
loci
(A) Lack of association with individual named ERAP1 markers after
controlling for association with the other ﬁve markers. This could not be
tested at rs30187 or rs27434 because they are in complete linkage
disequilibrium in this dataset
Marker Residual association
rs1065407 0.24
rs27044 0.28
rs30187 –
rs27434 –
rs31087–rs27434 0.36
rs2287987 0.6
rs26653 0.24
(B) Residual ERAP1 haplotypic association after controlling for the association
of the named marker
Marker Residual association
rs1065407 3.4   10
25
rs27044 0.00015
rs30187 0.00016
rs27434 0.00098
rs2287987 3.7   10
26
rs26653 3.4   10
25
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factors that control of ERAP1 expression. The potential impli-
cation of several ERAP1 nsSNPs in AS also underlines the
importance of solving its corresponding three-dimensional
protein structure which could be critical to understanding
how these polymorphisms affect its structure, function and
ability to interact with binding partners.
Two novel potentially disease-associated mutations were
identiﬁed exclusively in AS patients (V647I and C736R). It
is most likely that these variants were not observed in the
control population purely by chance but there is evidence
that similar private mutations in CARD15/NOD2 may be
associated with Crohn’s disease (27). In the absence of func-
tional studies illustrating the genotype–phenotype relation-
ship, validating such private mutations is extremely difﬁcult
because of the difﬁculty of conducting sufﬁciently powered
association studies.
There are two major putative functions of ERAP1 that could
explain its role in AS but our data do not help to distinguish
between them. These functions involve the cleavage of cell-
surface cytokine receptors (e.g. TNFR1) and peptide binding
to MHC class I molecules in the ER. TNFR1 shedding by
ERAP1 may decrease TNF bioactivity not only by reducing
the number of available cell-surface receptors to induce
TNFR1-mediated signaling but also by increasing the amount
of soluble TNFR1 that competes with cell-surface TNFR1 for
extracellular TNF (28,29). Loss of function ERAP1 variants
could clearly result in a pro-inﬂammatory state via these mech-
anisms. However, ERAP1 is not the ‘sheddase’ responsible for
actually cleaving TNFR1 in vitro and there is a need for
additional studies to provide supporting evidence for this func-
tion of ERAP1. In contrast, the peptide trimming function of
ERAP1 is well described. ERAP1 has been isolated from the
ER, where peptide binding to the nascent MHC class I mol-
eculesoccurs,andiRNAstudiessuggestitisinvolvedinthefor-
mation of about one-third of MHC-peptide complexes (9,30).
Functional studies of variant forms of ERAP1 could help
assess the role of this protein in peptide loading in patients
with AS and the general population.
To conclude, we have conﬁrmed the genetic association
between ERAP1 and AS and have identiﬁed a range of poly-
morphisms distributed throughout, and surrounding the gene
that are associated with AS. The most strongly associated
SNPs identiﬁed in this study by imputation reside within
ERAP1 regulatory sequences. Only with subsequent studies to
determine the impact of these polymorphisms on expression
and their structural and functional consequences is it likely that
the nature of the association with AS will ﬁnally be determined.
Figure 1. SNP association with AS against genomic location. Log10 P-value for imputed and genotyped SNPs plotted against physical distance. Aligned to the
plot are the genomic location of two ERAP1 isoforms and LD that exists in this region, red regions indicating high LD and blue indicating low LD.
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As cases and controls
All patients with AS were recruited with informed consent
(MREC project number 98/5/23) from patients attending the
Nufﬁeld Orthopaedic Centre (Oxford, UK), the Royal National
Hospital for Rheumatic Diseases (Bath, UK), the Centre for
Rheumatic Diseases (Glasgow, UK), members of the UK
National Ankylosing Spondylitis Society (NASS) or by refer-
ral from other British rheumatologists. All patients were
Figure 2. Comparison of the strength of association of various ERAP1 SNPs with AS and their inﬂuence on ERAP1 expression. P-values for association of SNPs
with AS generated by genotyping or imputation in our extended cases–control study were compared with P-values for SNP association with ERAP1 transcript
abundance from a previous study (using data from probe 209788_s_at) (18). Only a subset of 32 SNPs are plotted which were used in both studies.
Figure 3. Ribbon model of putative ERAP1 structure. Highlighted are the active site around the central Zn atom (red sphere) in cyan and the positions of residues
affected by non-synonymous polymorphisms associated with AS in this study, including rare novel variants V647I and C736R.
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criteria for AS (31). DNA was prepared from peripheral blood
leucocytes by standard methods. For comparison in both the
replication and ﬁne-mapping extended study we used 1021
ethnically matched healthy subjects, who were either blood
donors or spouses of patients with osteoarthritis.
Independent ERAP1 replication study
We genotyped four SNPs in ERAP1 in 730 unrelated AS cases
and 1021 healthy controls by iPLEX technology, which is
based on a single base pair primer extension followed by mass
spectrometry (MassARRAY
w, Sequenom, San Diego, USA).
Caseandcontrolgenotypefrequencies werecompared and stats-
ticalsigniﬁcancewastestedusingtheCochrane–Armitagetestof
trend. Finally, using the StatsDirect statistical package (http
://www.statsdirect.com. England: StatsDirect Ltd. 2008) we
tested for heterogeneity between our replication cohort and the
WTCCC-TASC data (1000 AS cases compared with 1500 con-
trols from the 1958 British Birth Cohort and 2879 disease
control individuals with multiple sclerosis, autoimmune thyroid
disease or breast cancer which are not associated with ERAP1)
usingtheCochranQstatistic.Subsequently,basedonaninsignif-
icant Cochran Q P-value, a meta-analysis was performed using
the Mantel–Haenszel test for ﬁxed effects OR.
ERAP1 sequencing
The 20 exons, intron–exon boundaries and 50-UTR of ERAP1
were sequenced in 48 new AS cases. The consensus sequence
was obtained from Ensembl Genome Browser (http://www.
ensembl.org/). Primers were designed for PCR products of
400–550 bp with overlapping PCR products for target
regions .550 bp. Sequencing was carried out using BigDye
v3.1 (Applied Biosystems, Warrington, UK) followed by puri-
ﬁcation using Pellet Paint
w Co-Precipitant (Novagen, Northum-
berland, UK). Finally, samples were added to HiDi formamide
and analyzed using an AB3100 Genetic Analyzer (Applied
Biosystems, Warrington, UK). All sequence variants were
identiﬁed by manual inspection of the electropherograms
using the software program SeqScape v2.1. ERAP1 sequence
data were used to calculate statistical measures of LD
between SNPs using the LDMAX programme (32).
Extended ERAP1 case–control study
Twenty-three SNPs (six tagging SNPs, with r
2 . 0.8 identiﬁed
from the ERAP1 sequencing data, the remaining nine sequence
variants,twoSNPsinthe50-UTRandthesixnovelsequencevar-
iants) were selected for genotyping in 1604 AS cases (a combi-
nation of AS cases included in the original WTCCC-TASC
study and our independent replication and sequencing studies)
and1021controls(usedinthereplicationstudy).SNPsweregen-
otyped by iPLEX technology and statistical signiﬁcance was
tested using the Cochrane–Armitage test of trend using the
PLINK program (33). Assays were initially run using CEPH
HapMap individuals to conﬁrm they were functioning correctly
and their genotype clusters used as a reference for the test
subjects. Markers that failed Hardy–Weinberg equilibrium in
controls or were missing .10% of genotypes were excluded
from analyses. We also manually checked genotype calls for
each SNP by inspecting the cluster plots to ensure three distinct
clusters were apparent and any outliers excluded. The power to
detect an association to an OR of 1.2 was calculated using a log
additive model, assuming prevalence of 0.4%, observed case
and control allele frequencies, and an alpha level of 0.05. Con-
ditional logistic regression analyses involving the six most sig-
niﬁcantly associated SNPs were performed using PLINK (33).
An omnibus six marker test was carried out and we tested
whether any SNP had an effect independent of the background
haplotypic association.
Imputation analyses were carried out using Markov Chain
Haplotyping software (MaCH 1.0) using phased data from
CEU individuals from release 22 of the HapMap project (www.
hapmap.org) as the reference set of haplotypes (www.sph.
umich.edu/csg/abecasis/mach/index.htm). We only analyzed
SNPs that were either genotyped or could be imputed with rela-
tively high conﬁdence (r
2 . 0.3). Association analysis of
imputed SNPs was performed assuming an underlying additive
model using the software package MACH2DAT (Li, Willer,
Ding, Scheet and Abecasis, unpublished data) which accounts
for uncertainty in prediction of the imputed data by weighting
genotypes by their posterior probabilities. To evaluate imputed
P-values against LD blocks we constructed an LD plot with the
LDMAX and GOLD programs using the HapMap and genotype
data used for imputation (32).
Comparison with erap1 cis-SNP expression data
A recent study of 400 children with/without childhood asthma
generated strong evidence that certain ERAP1 expression traits
are both heritable and under cis-acting regulatory control.
Dixon and colleagues genotyped 400 children from 206
families (recruited through a proband with childhood
asthma) across a panel of .400 000 genome-wide SNPs. Sub-
sequently, by microarray, they measured transcript abundance
levels of 20 599 genes in EBV-transformed Lymphoblastoid
cell lines (20). Finally, they tested for association between
the genotype at each locus and the abundance of each tran-
script enabling the generation of a comprehensive expression
QTL (eQTL) database. We searched this database for sites
which inﬂuence the abundance of ERAP1. Data were available
from a total of seven Affymetrix U133 Plus 2.0 probes, three
of which (209788_s_at, 210385_s_at and 214012_at) detected
strong ERAP1 expression with maximal signiﬁcance at
marker rs28096 (P-value ¼ 1.6   10
232) observed through
probe 209788_s_at. Variation in heritability and expression
between probes may indicate the presence of ERAP1 splice var-
iants, only a proportion of which are subject to genetic regu-
lation (in particular at this site). Together these data suggest
that a number of SNPs have signiﬁcant cis-acting effect(s) on
the expression of ERAP1, and that this effect (or effects) may
be transcript speciﬁc. Therefore, we tested for a correlation
between association of SNPs with AS from our study and
association with ERAP1 expression from their data.
Molecular modeling of ERAP1 structure
Human ERAP1 was modeled using the ICM program
(Molsoft, San Diego) with the M1 aminopeptidase family
4210 Human Molecular Genetics, 2009, Vol. 18, No. 21member tricorn-interacting factor 3 (34) (PDB id 1z1w),
which shares 25.5% homology with ERAP1, as the structural
template.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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